Literature DB >> 33382431

Polylactose Exhibits Prebiotic Activity and Reduces Adiposity and Nonalcoholic Fatty Liver Disease in Rats Fed a High-Fat Diet.

Breann E Abernathy1, Tonya C Schoenfuss1, Allison S Bailey1, Daniel D Gallaher1.   

Abstract

BACKGROUND: Prebiotic dietary fibers change the intestinal microbiome favorably and provide a health benefit to the host.
OBJECTIVES: Polylactose is a novel fiber, synthesized by extrusion of lactose. We evaluated its prebiotic activity by determining its fermentability, effect on the microbiota, and effects on adiposity and liver lipids in a diet-induced obesity animal model.
METHODS: Male Wistar rats (4-5 wk old) were fed normal-fat (NF, 25% fat energy) or high-fat (HF, 51% fat energy) diets containing different fibers (6% fiber of interest and 3% cellulose, by weight), including cellulose (NFC and HFC, negative and positive controls, respectively), polylactose (HFPL), lactose matched to residual lactose in the HFPL diet, and 2 established prebiotic fibers: polydextrose (HFPD) and fructooligosaccharide (HFFOS). After 10 wk of feeding, organs were harvested and cecal contents collected.
RESULTS: HFPL animals had greater cecum weight (3 times greater than HFC) and lower cecal pH (∼1 pH unit lower than HFC) than all other groups, suggesting that polylactose is more fermentable than other prebiotic fibers (HFPD, HFFOS; P < 0.05). HFPL animals also had increased taxonomic abundance of the probiotic species Bifidobacterium in the cecum relative to all other groups (P < 0.05). Epididymal fat pad weight was significantly decreased in the HFPL group (29% decrease compared with HFC) compared with all other HF groups (P < 0.05) and did not differ from the NFC group. Liver lipids and cholesterol were reduced in HFPL animals when compared with HFC animals (P < 0.05).
CONCLUSIONS: Polylactose is a fermentable fiber that elicits a beneficial change in the gut microbiota as well as reducing adiposity in rats fed HF diets. These effects of polylactose were greater than those of 2 established prebiotics, fructooligosaccharide and polydextrose, suggesting that polylactose is a potent prebiotic.
© The Author(s) 2020. Published by Oxford University Press on behalf of the American Society for Nutrition.

Entities:  

Keywords:  adiposity; fatty liver; fermentation; liver cholesterol; microbiota; prebiotic; rat

Mesh:

Substances:

Year:  2021        PMID: 33382431      PMCID: PMC8096245          DOI: 10.1093/jn/nxaa376

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  67 in total

1.  The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Anna Mae Diehl; Elizabeth M Brunt; Kenneth Cusi; Michael Charlton; Arun J Sanyal
Journal:  Gastroenterology       Date:  2012-05-15       Impact factor: 22.682

Review 2.  Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics.

Authors:  Glenn R Gibson; Robert Hutkins; Mary Ellen Sanders; Susan L Prescott; Raylene A Reimer; Seppo J Salminen; Karen Scott; Catherine Stanton; Kelly S Swanson; Patrice D Cani; Kristin Verbeke; Gregor Reid
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-06-14       Impact factor: 46.802

Review 3.  Non-Alcoholic Fatty Liver Disease, an Overview.

Authors:  Asia Muhammad Nd
Journal:  Integr Med (Encinitas)       Date:  2019-04

4.  Microbial ecology: human gut microbes associated with obesity.

Authors:  Ruth E Ley; Peter J Turnbaugh; Samuel Klein; Jeffrey I Gordon
Journal:  Nature       Date:  2006-12-21       Impact factor: 49.962

5.  Resistant maltodextrin or fructooligosaccharides promotes GLP-1 production in male rats fed a high-fat and high-sucrose diet, and partially reduces energy intake and adiposity.

Authors:  Tohru Hira; Ryoya Suto; Yuka Kishimoto; Sumiko Kanahori; Hiroshi Hara
Journal:  Eur J Nutr       Date:  2017-02-04       Impact factor: 5.614

Review 6.  From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites.

Authors:  Ara Koh; Filipe De Vadder; Petia Kovatcheva-Datchary; Fredrik Bäckhed
Journal:  Cell       Date:  2016-06-02       Impact factor: 41.582

7.  Prebiotic and Synbiotic Modifications of Beta Oxidation and Lipogenic Gene Expression after Experimental Hypercholesterolemia in Rat Liver.

Authors:  Claudia C Alves; Dan L Waitzberg; Laila S de Andrade; Laís Dos Santos Aguiar; Milene B Reis; Camila C Guanabara; Odair A Júnior; Daniel A Ribeiro; Priscila Sala
Journal:  Front Microbiol       Date:  2017-10-17       Impact factor: 5.640

8.  Human-origin probiotic cocktail increases short-chain fatty acid production via modulation of mice and human gut microbiome.

Authors:  Ravinder Nagpal; Shaohua Wang; Shokouh Ahmadi; Joshua Hayes; Jason Gagliano; Sargurunathan Subashchandrabose; Dalane W Kitzman; Thomas Becton; Russel Read; Hariom Yadav
Journal:  Sci Rep       Date:  2018-08-23       Impact factor: 4.379

Review 9.  Microbial degradation of complex carbohydrates in the gut.

Authors:  Harry J Flint; Karen P Scott; Sylvia H Duncan; Petra Louis; Evelyne Forano
Journal:  Gut Microbes       Date:  2012-05-10

10.  Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease.

Authors:  Sonia Michail; Malinda Lin; Mark R Frey; Rob Fanter; Oleg Paliy; Brian Hilbush; Nicholas V Reo
Journal:  FEMS Microbiol Ecol       Date:  2014-12-05       Impact factor: 4.519

View more
  1 in total

Review 1.  Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role.

Authors:  Haripriya Gupta; Byeong-Hyun Min; Raja Ganesan; Yoseph Asmelash Gebru; Satya Priya Sharma; Eunju Park; Sung-Min Won; Jin-Ju Jeong; Su-Been Lee; Min-Gi Cha; Goo-Hyun Kwon; Min-Kyo Jeong; Ji-Ye Hyun; Jung-A Eom; Hee-Jin Park; Sang-Jun Yoon; Mi-Ran Choi; Dong-Joon Kim; Ki-Tae Suk
Journal:  Biomedicines       Date:  2022-02-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.